Arabic Arabic English English French French German German
dark

Aura Biosciences Announces Pricing of Initial Public Offering

Aura Biosciences, Inc. (“Aura”), a clinical-stage oncology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the pricing of its initial public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

MDimune pens FAF1 mRNA cancer drug deal with Kainos Medicine

Next Post

Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021

Related Posts
Total
0
Share